Загрузка...
Adverse Events of Monoclonal Antibodies Used for Cancer Therapy
In 1997, the first monoclonal antibody (MoAb), the chimeric anti-CD20 molecule rituximab, was approved by the US Food and Drug administration for use in cancer patients. Since then, the panel of MoAbs that are approved by international regulatory agencies for the treatment of hematopoietic and solid...
Сохранить в:
| Опубликовано в: : | Biomed Res Int |
|---|---|
| Главные авторы: | , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Hindawi Publishing Corporation
2015
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4436450/ https://ncbi.nlm.nih.gov/pubmed/26075239 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2015/428169 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|